Literature DB >> 10796061

Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers.

P Schiavi1, R Jochemsen, D Guez.   

Abstract

The pharmacokinetics of a 2.5 mg immediate release (IR) formulation of indapamide was compared to a 1.5 mg sustained release (SR) formulation of indapamide after single and repeated oral administration dose using double blind randomised cross-over studies. In the first study, 12 subjects received a single dose of each treatment: IR fasted, SR fasted or with food. In the second study one tablet of either formulation was administered daily for one week at breakfast. In each study, blood samples were collected pre dose (Cmin) and up to 120 h after the last dose. Urine was collected over the dosing interval (24 h). Following a single oral administration the SR formulation had a lower dose-normalised Cmax compared to the IR formulation (17.6 +/- 6.3 vs. 39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h). The SR formulation clearly demonstrated sustained release characteristics as compared to the IR formulation. Food co-administration had no effect on dose-normalised AUC for the SR formulation. After repeated administration, steady-state was achieved by day 5. The absorption rate of the SR formulation was lower and the 24 h peak-to-trough fluctuation was 4-fold lower compared to the IR formulation. After dose correction there wasno change in AUC, (726 +/- 207 and 690 +/- 183 ng x mL(-1) x h for SR and IR, respectively). The elimination parameters (t(1,2z), Ae(tau), and CLr) remained unchanged. The SR formulation showed sustained release of indapamide with a reduction in peak concentration, while steady-state level was not affected by formulations. The two formulations have the same bioavailability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796061     DOI: 10.1111/j.1472-8206.2000.tb00402.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.

Authors:  Teng-Hsu Wang; Cheng-Huei Hsiong; Hsin-Tien Ho; Tung-Yuan Shih; San-Jan Yen; Hui-Hung Wang; Jer-Yuarn Wu; Benjamin Pei-Chung Kuo; Yuan-Tsong Chen; Shung-Tai Ho; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-12-20       Impact factor: 4.009

Review 2.  Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic.

Authors:  Wanpen Vongpatanasin
Journal:  Curr Opin Cardiol       Date:  2015-07       Impact factor: 2.161

Review 3.  Indapamide sustained release: a review of its use in the treatment of hypertension.

Authors:  Dean M Robinson; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.

Authors:  P Weidmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Efficacy and Acceptability of Indapamide Sustained Release in Elderly High-Risk Hypertensive Patients : the ARGUS Study.

Authors:  Zhanna D Kobalava; Yulia V Kotovskaya; Valentin S Moiseev
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

6.  Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2010-05-10

Review 7.  Which thiazide to choose as add-on therapy for hypertension?

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2014-07-30

8.  Simultaneous determination of indapamide, perindopril and perindoprilat in human plasma or whole blood by UPLC-MS/MS and its pharmacokinetic application.

Authors:  Yi Tao; Sheng Wang; Lei Wang; Min Song; Taijun Hang
Journal:  J Pharm Anal       Date:  2018-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.